Bayer AG shares hover on a razor‑thin line as two court dates loom. Investors track a U.S. Supreme Court decision on Monsanto’s Roundup label claims and a fairness hearing over a $7.25 billion class‑action settlement. The company has already shed $60 billion in market value since its Monsanto purchase.

If the Supreme Court sides with Bayer, failure‑to‑warn theories evaporate, clearing the path for a clean earnings forecast. Jefferies analyst Michael Leuchten projects the stock could climb to €50. A loss would drag shares toward €30, adding a double‑digit billion‑euro provision to an already stretched balance sheet and pending lawsuits worldwide for investors.

The July 9 fairness hearing in Missouri faces a location dispute as opponents push for a San Francisco venue, hoping a federal judge will reject the settlement’s terms. Bayer argues Missouri courts remain proper, citing its 65,000 current suits and the need to keep litigation timelines predictable for shareholders and future payouts to investors today.

Beyond Roundup, Bayer confronts lingering PCB lawsuits that could add billions to its liabilities. With a potential Supreme Court win, the company could unlock a consumer‑health spin‑off, boosting its sum‑of‑parts value to €60. Yet, without legal clarity, the stock remains a high‑risk play for investors in a volatile market landscape that demands cautious positioning today.